Combination Therapy for Glioblastoma: A Personalized, AI-Driven Approach
Discover how AI-driven models and patient-derived xenografts are advancing personalized combination therapies for glioblastoma.
Understanding Biological Material Licensing for Preclinical Research
Learn why biological material licensing matters in preclinical research, what risks to avoid, and how to manage licenses for cell lines, organoids, PDX models, and more.
Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI
Join Dr. Michael Boice from Certis Oncology for a discussion and demonstration of how artificial intelligence can improve preclinical decision-making in cancer research.

